Health Problems After Travel to Developing Countries by Steffen, Robert et al.
THE JOURNAL OF INFECTIOUS DISEASES • VOL. 156, NO.1. JULY 1987
© 1987 by The University of Chicago. All rights reserved. 0022-1899/87/5601-0011$01.00
Health Problems After Travel to Developing Countries
Robert Steffen, Martin Rickenbach, Urs Wilhelm,
Andree Helminger, and Meinrad Schar
From the Vaccination Center, Institute jor Social and
Preventive Medicine of the Zurich University,
Zurich, Switzerland
Travelers to developing countries participated in a follow-up study of the health risks as-
sociated with short (less than three months) visits to these nations. Travelers to the Greek
or Canary Islands served as a control cohort. Participants completed a questionnaire to
elicit information regarding pretravel vaccinations, malaria prophylaxis, and health prob-
lems during and after their journey. Relevant infections were confirmed by the respon-
dent's personal physician. The questionnaire was completed by 10,524 travelers; the an-
swer rate was 73.8070. After a visit to developing countries, 15% of the travelers reported
health problems, 8% consulted a doctor, and 3% were unable to work for an average
of 15 days. The incidence of infection per month abroad was as follows:giardiasis, 7/1,000;
amebiasis, 4/1,000; hepatitis, 4/1,000; gonorrhea, 3/1,000; and malaria, helminthiases,
or syphilis, <1/1,000. There were no cases of typhoid fever or cholera.
Recommendations for disease prophylaxis before
travel to developing countries should be based on
well-founded information about potential health
risks. Some general surveys of health problems in-
curred during a stay abroad exist [1-3], but these
studies did not examine infections with longer incu-
bation periods. Surveys on specific diseases, such as
malaria [4], hepatitis [5-9], typhoid fever [10, 11],
other salmonelloses and shigelloses [12], cholera [13,
14], or travelers' diarrhea [15] may have missed cases
or may have been partly biased by the retrospective
approach [16].The complete lack of data on travelers
with chronic diarrhea after a stay in developing coun-
tries has recently been criticized [17]. Reports from
clinics in tropical medicine only describe select and
nonrepresentative populations.
Therefore, a follow-up study was set up to ana-
lyze incidence and importance of health risks, nota-
bly including diseases apparent only after a
prolonged incubation period. Because >80OJo of the
tourists traveling to developing countries are vaca-
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tioners, we concentrated on short-term visitors. Swit-
zerland was suitable for such a project because 8OJo
of its population visits developing countries each
year [18]. Per capita, no other population spends
more on international travel [19].
Subjects and Methods
Between July 1981and June 1984, travelers ~12 years
of age wererecruited and given a brief bilingual (Ger-
man/French) questionnaire. This questionnaire was
distributed either during or just before boarding 112
charter and 12 scheduled flights to developing coun-
tries and to persons traveling by car or rail to Asia
or Africa. Similarly, during one year, a minimal risk
cohort was recruited as a control group from pas-
sengers on 19charter flights to Rhodes, Kos, or Crete
(Greece) and the Canary Islands (Spain). Only name,
home address, destination, and duration of stay
abroad were recorded in this first questionnaire.
Within this sample (travelers and control cohort)
all those residing outside German-speaking Switzer-
land wereexcluded to enable an easier follow-up. The
remaining travelers who had indicated that they
would stay abroad no longer than three months re-
ceived a second, retrospective questionnaire that was
sent out seven months after departure (4-6.75
months after return). This questionnaire examined
personal data, vaccinations, malaria prophylaxis,
health problems during and after the journey as listed
in table 3, need for medical services, and length of
sick leave. If they wished, the persons could tear off
the serial number to remain anonymous. In the fur-
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ther evaluation, questionnaires with confusing an-
swerswere excluded (table 1,exclusion II). In all rele-
vant illnesses (table 5), the doctors treating the
patient were asked to complete a third questionnaire
and to send the laboratory results to confirm or cor-
rect the diagnosis reported by the patient. Diagno-
sis was considered "definite" if a large laboratory had
evaluated the serological specimens. The diagnosis
of non-A, non-B hepatitis was based on negative ser-
rological tests for hepatitis A or hepatitis B virus in-
fection, but hepatitis delta virus, cytomegalovirus,
and Epstein-Barr virus infections werenot excluded
in all cases at the time of the investigation. Similarly,
malaria, giardiasis, and amebiasis were considered
"definite" when diagnosed in a hospital or by a doc-
tor trained in tropical medicine; gonorrhea was ac-
cepted as "definite" when diagnosed in a smear by
any doctor. Diagnosis was considered "possible" if
such criteria were not fulfilled. Patients with hepa-
titis A or gonorrhea with too long an incubation
period [20] were excluded. Chronic diarrhea was de-
fined as persisting illness with at least three unformed
'daily stools, which resulted in at least five medical
consultations, hospitalization of at least five days,
inability to work for at least 15 days, or no cure by
the time of the investigation.
The following travel characteristics weredifferen-
tiated. A beach vacation was limited to a stay in one
hotel only; guided tours wereaccompanied by a guide
with lodging in international hotels. In individual
tours the travelers stayed in international hotels with-
out a guide; in adventure tours they lived in tents
or cheap 'boarding houses. The other terms for travel
and for destinationshave been previously described
[15].
Statistical evaluation was done by A. H. at the
Zurich University Calculation Center by using an
IBM 3033 with the SPSS-X program package. The
r} test with Yates' correction was used to compare
rates. When indicated, standard deviations are
documented. To identify high-risk groups, we per-
formed a multiple logistic regression analysis.
Results
Recruitment of the population is demonstrated in
table 1. For those indicated in table 1 as exclusion
I, in 98070 of the instances the reason was residence
outside German-speaking Switzerland. Exclusion II
mainly resulted from travelers taking a second jour-
ney to developing countries. Three of the question-
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Table 1. Travelers recruited for this study.
Destination
Developing Greek/Canary
Questionnaire country Islands Total
First questionnaire
No. distributed 31,608 4,416 36,024
No. answered 24,242 3,701 27,943
Answer rate (070) 76.7 83.8 77.6
Exclusion I 12,990 693 13,683
Second questionnaire
No. distributed 11,252 3,008 14,260
No. answered 8,192 2,332 10,524
Answer rate (070) 72.8 77.6 73.8
Exclusion II 306 36 342
Total no. of travelers
evaluated 7,886 2,296 10,182
naires (including two from the control group) were
returned unanswered because the addressee had died
for reasons unrelated to his journey. Fifty-two
respondents remained anonymous.
Table 2 shows the characteristics of the popula-
tion and of the journey. The mean age of the travelers
was 39.9 ± 14.2 (control group, 32.9 ± 13.5) years;
the mean duration of stay was 2.8 ± 1.6weeks (con-
trol group, 2.1 ± 0.8 weeks). Health problems were
significantly more frequent in young adults, visitors
to West Africa, people on adventure tours, and in
those groups who lived with natives, who went to
work abroad, or who stayed for a prolonged period'
of time. In contrast, older travelers, visitors to East
Africa or to Sri Lanka/Maldives, and those on
guided tours were ill less often. Unless otherwise
noted, the multiple logistic regression analysis of
any single illness or accident showed no correlation
with age, sex, destination, or season of travel. Table
3 contains type and period of occurrence of the main
symptoms. The consequences of illness and accidents
are listed in table 4.
No cases of typhoid fever, cholera, poliomyelitis,
tuberculosis, or tetanus were reported. The illnesses
diagnosed by medical professionals are summarized
in table 5.
Diagnosis of malaria was difficult to certify be-
cause more than half of the patients had been treated
abroad and often were not evaluated by examina-
tion of a blood smear. Eleven of the twelve definite
or possible cases of malaria originated in Africa. Two
of these patients belonged to the 2.7070 of all travelers
to endemic areas who refused all prophylactic medi-
cation; four admitted that they did not comply with
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Table 2. Proportion of travelers who reported health problems.
Developing countries Greek/Canary Islands
1,426 98 (6.9)
839 78 (9.3)
31 2 (6.5)
2,089 160 (7.7)
154 17 (11.0)
105 9 (8.6)
139 14 (10.1)
108 14 (13.0)
76 5 (6.6)
2,276 176 (7.7)
4 1 (25.0)
9 1 (11.1)
2,275 175 (7.7)
21 3 (14.3)
2,296 178 (7.8)
No. of No. of
Characteristics travelers" health problems (070)
Sex
Men 4,155 620 (14.9)
Women 3,712 548 (15.7)
Age-group
0-19 238 36 (15.1)
20-29 2,114 428 (20.2)§
30-39 1,848 294 (15.9)
40-49 1,469 194 (13.2)
50-59 1,352 160 (11.8)t
60-69 651 68 (10.4)t
70-87 181 26 (14.3)
Destination
East Africa 2,628 340 (12.9)t
West Africa 1,473 304 (20.6)§
Sri Lanka/Maldives 2,085 270 (12.9)t
Far East (east of Burma) 531 72 (13.6)
Asia, various regions 328 58 (17.7)
South America 717 134 (18.7)
Greek Islands
"Canary Islands +
Various/other regions 124 27 (21.8)
Travel characteristics (several answers possible)
Beach vacation 5,156 757 (14.7)
Guided tours 3,365 458 (13.6)t
Individual tours 1,169 203 (17.4)
Adventure tours 1,171 218 (l8.6)t
Lived with locals 736 139 (l8.9)t
Lived with white
(control, Swiss) residents 403 73 (18.1)
Reason for journey
Vacation 7,317 1,098 (15.0)
Work, business 97 20 (20.6)
Visit, various 458 90 (l9.7)t
Duration of stay abroad
Up to one month 7,348 1,070 (14.6)
Over one month 533 139 (26.1)§
Total 7,886 1,209 (15.3)
No. of
travelers*
1,027
1,265
239
949
403
375
227
71
20
No. of
health problems (070)
71 (6.9)
107 (8.5)
19 (7.9)
81 (8.5)
38 (9.4)
27 (7.2)
9 (4.0)
3 (4.2)
o (0.0)
NOTE. The marginal distribution of the "health problems" variable served as a reference in the statistical analysis.
* Numbers do not add up to total, as some respondents did not answer all questions.
t p < .01.
:I: p < .001.
§ p < .0001.
the prophylactic regimen. In three patients who had
received single-agent prophylaxis but had acquired
malaria in Kenya, parasite resistance to chloroquine,
pyrimethamine, or Fansidarf was noted. In the re-
maining three patients, no explanation for their pos-
sible malaria could be found. Concordant with the
Swiss doctrine, 750,10 of the visitors to Southeast Asia
and South America took Fansidar prophylactically,
but only one patient had malaria that originated in
the Far East; this patient did not comply with the
prophylactic regimen. Four definite cases were due
to Piasmodium falciparum; the remaining one (the
one from Asia) was due to Plasmodium vivax.
In hepatitis A and non-A, non-B hepatitis, no sub-
population with specific travel characteristics had a
significantly increased or diminished incidence, in-
cluding those travelers who took a brief beach vaca-
tion. The mean duration of inability to work due
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Table 3. Subjective description of the health problems reported by 1,209 of 7,886 short-term visitors to developing
countries.
Illness in travelers to developing countries
Proportion ill (0/0)
No. of illnesses in
Abroad Abroad Upon return travelers to Greek/
Symptom" No. of cases (%) only and home only Canary Isl~nds (%)
Severe diarrhea 674 (8.5) 58 30 12 77 (3.4)
Vomiting or abdominal cramps 315 (4.0) 54 31 15 49 (2.1)
Common cold 171 (2.2)t 41 40 19 23 (1.0)
High fever over several days 152 (1.9)t 39 37 24 18 (0.8)
Dermatosis 97 (1.2) 31 36 33 26 (1.1)
Chills 87 (1.1) 29 41 30 10 (0.4)
Discharge (vagina/urethra) 49 (0.6)t 20 43 37 8 (0.3)
Severe constipation 45 (0.6) 57 39 4 8 (0.3)
Accident 38 (0.5) 25 62 13 14 (0.6)
Jaundice 24 (0.3) 17 29 54 3 (0.1)
Genital ulcer 9 (0.1) 25 12 63
Various 217 (2.8) 29 40 31 26 (1.1)
Total with health problems 1,209 (15.3) 47 32 21§ 178 (7.8)
* Several answers per traveler were possible.
t Women were more affected (P = .02).
t More days of illness if stay exceeded four weeks (P = .05).
§ In first week, 10%; in second to fourth week, 8%; the rest occurred later.
to hepatitis was 33 days. No other disease accounted
for so many sick-days.
Chronic diarrhea was found in 73 (0.9070) travelers.
The highest rate (1.8070) was noted upon return from
West Africa and after journeys through various
Table 4. Consequences of health problems.
regions of the Far East (P = .002). One-third of the
patients became symptomatic only after returning
home - some after a delay exceeding one month.
Chronic diarrhea ranked second in days of inability
to work. Ten cases each were associated with amebi-
Destination
Consequences
Medical consultations, numbers of travelers
Doctor abroad
Family physician after return
Specialist in tropical medicine after return
Various specialists after return
Outpatient clinic after return
Mean no. of visits
Hospitalization
1 day only
2-7 days
>1 week
Inability to work
Mean duration (days) in those with inability
Mean duration (days) in entire surveyed sample
Not restored to health at the time of investigation
Developing countries
659 (8.4)
210 (2.7)*
331 (4.2)
123 (1.6)
76 (1.0)
42 (0.5)
4.0 ± 5.2 (median, 3)
43 (0.5)t
9 (0.1)
12 (0.2)
22 (0.3)
241 (3.1)
15.1 ± 19.1 (median, 7)
0.46
75 (1.0)t
Greek/Canary Islands
61 (2.7)
31 (1.3)
30 (1.3)
7 (0.3)
3 (0.1)
1.2 ± 2.4
1 (0.04)
1 (0.04)
26 (1.1)
6.3 ± 4.7 (median, 5)
0.07
9 (0.4)
NOTE. Unless otherwise specified, data are no. of travelers (%).
* Sought consultation mainly because of severe diarrhea, fever, or dermatosis.
t Hospitalized mainly because of diarrhea of undetected origin, amebiasis, or hepatitis.
t Health was not restored mainly because of parasitosis, diarrhea of undetected origin, or accident.
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Table 5. Relevant infections in 7,886 short-term visi-
tors to developing countries.
Diagnosis of illness
in travelers to
developing countries
Steffen et al.
difference in any symptom was found between the
travelers to the Greek and the Canary Islands.
Discussion
NOTE. In the control group, travelers to the Greek/Canary
Islands, there was only one "possible" case of illness diagnosed:
hepatitis B (see text).
* Subject worked with native population.
t Mostly men had gonorrhea.
asis or giardiasis, and a few were associated with
helminthiasis; however, the majority of cases were
of undetected origin. Giardiasis, amebiasis, and hel-
minthiasis occurred less frequently in vacationers
than in those who worked or stayed with natives
(P = .004).
Accidents affected 38 (0.5070) travelers; 32 of them
sought medical attention, and 10had to be hospital-
ized, half of them for more than a month. The most-
severe cases resulted from traffic accidents (n = 3)
or assaults (n = 2), whereas the most-frequent ones
resulted from lacerations received during water sports
(n = 17).
In the control cohort, far less (7.8070 vs. 15.3%,
P < .0001) serious health problems were reported.
Travelers to the Greek or the Canary Islands also
reported fewer relevant symptoms (tables 3 and 4).
No cases of severe infection were confirmed (table
5). Although hepatitis B was proven in a patient, he
may have been infected while still in Switzerland
through contact with a drug abuser who had hepa-
titis B. Only six cases of chronic diarrhea were
recorded; none persisted at the time of the investi-
gation. Only dermatological problems (mainly sun-
burn) and accidents occurred slightly more fre-
quently in the control group. No significant
Illness
Malaria
Hepatitis (all)
Hepatitis A
Hepatitis B
Hepatitis, non-A, non-B
Hepatitis, unclassified
Giardiasis
Amebiasis
Helminthsiasis
Paratyphoid B
Salmonellosis, other
Shigellosis
Gonorrhea
Syphilis
Definite
5
23
8
2*
9
4
34
22
5
1
5
1
17t
2
Possible
7
4
4
4
8
2
This study is representative for Swiss-German
tourists vacationing in the most-popular developing
countries and on the Greek and the Canary Islands.
The high response rate to our questionnaire shows
that the vast majority of travelers to developing coun-
tries are aware and concerned about possible medi-
cal problems. The difference in the mean age between
the study and the control cohort is explained by the
fact that younger people, mainly women, cannot af-
ford the longer trip and prefer beach vacations. Pos-
sible biases must be considered - mainly difficulties
in recall and lack of uniform standard of diagnosis.
The study sample was not controlled with respect
to prophylaxis, exposure, and treatment; therefore,
the study realistically illustrated the variations in a
tourist population.
Figure 1 summarizes the incidence rates of infec-
tions. A slight inexactness may arise from extrapolat-
ing from a 2.8-week to a one-month stay; e.g., in di-
arrhea the incidence decreases with time. With
exceptions to be discussed below, the rates provided
by former retrospective case-history studies are con-
firmed by this follow-up study. In general, age, des-
tination, travel characteristics, and, above all, dura-
tion of stay abroad playa significant role. High-risk
travelers, therefore, need more-detailed medical
recommendations. A very high risk for any single
serious health problem, which could have been
prevented by drug or immunization prophylaxis, was
not more prevalent in anyone subgroup.
Malaria was imported from Africa at a rate of
97.6/100,000; this rate includes only definite cases.
The Centers for Disease Control (CDC; Atlanta, Ga)
calculated an attack rate of 108.0/100,000 in U.S.
travelers to Kenya [21]. Imported malaria, however,
illustrates only a part of the problem, as even in
short-term travelers an important proportion of cases
is treated abroad and is not reported. Increasing dis-
tribution of chloroquine-resistant R jalciparum and
growing concern about adverse reactions due to Fan-
sidar [22, 23] and amodiaquine [24, 25] are likely
to lead to diminished protection of the travelers visit-
ing endemic areas and to a further increase in the
incidence of malaria. A more-detailed analysis of
the risk of malaria with respect to different types
of prophylaxis has just been published [26].
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Figure 1. Incidence of infections per 100,000 travelers
for a stay of one month in a developing country. The inci-
dence rates per month were calculated by multiplying the
rate for the mean duration of stay of 2.8 weeks by a factor
of 1.53.AKTI = acute respiratory tract infection, TF = ty-
phoid fever.
Hepatitis A, non-A, non-B hepatitis, or hepatitis
B affected 291.6(hepatitis A only, 101.4)/100,000 vis-
itors to developing countries in the 2.8-week stay.
This is three times the rate observed in most retrospec-
tive surveys [5-7], which were usually performed be-
fore serological differentiation was possible, and is
five times more than the rate observed in the pre-
liminary CDC report [1], which, however, included
travelers to Europe. As noted [5, 8], a considerable
proportion of cases was missed in the older case-
history surveys. In contrast, a Swedish source has
reported a higher rate of 600-1,000/100,000 travelers
exclusively for hepatitis A for a mean stay abroad
of two weeks [9]. In our study, some cases of hepa-
titis A may have been counted as unclassified hepa-
titis, as antibody to hepatitis A virus was not yet
regularly assessed in the early 1980s. The high pro-
portion of non-A, non-B hepatitis (table 5) proba-
bly results from chance, as usually non-A, non-B
hepatitis accounts for only 20070 of all cases of im-
ported hepatitis [7]. Although seven of those nine
patients took Fansidar, the prolonged course of hep-
atitis is not suggestive of a sulfonamide drug reac-
tion [27].
Hepatitis occurred exclusively in travelers who had
not received immunoglobulin. Such prophylaxis is
given only to 5070 of Swiss travelers (mainly adven-
turers) to developing countries (Steiger E, unpub-
lished observation). With such protection, this high-
risk group may therefore not appear as excessively
exposed as in a former survey [5]. Travelers eating
and drinking exclusively in tourist-class accommoda-
tions are at less risk [28], but our results indicate that
the risk of hepatitis in this group is currently being
underestimated [28]. Prophylactic immunoglobulin
may be suggested for each traveler to a developing
country. This prophylaxis would be expensive but
may well have a benefit worth the additional cost
[29], even if it protects only 85070 from hepatitis A
[30]. A claimed protection against non-A, non-B
hepatitis [31] remains unconfirmed.
Although almost no Swiss traveler was effectively
immunized against typhoid fever [32] and only a few
were immunized against cholera, no infections were
reported. This adds evidence to the fact that it is suf-
ficient to recommend typhoid vaccination mainly for
travelers "off the usual tourist itinerary" [28] and to
those visiting India [32]. Cholera vaccination is cer-
tainly not to be advised to all visitors to Asia and
Africa; however, some authors from both sides of
the Atlantic still do so [33, 34], and this procedure
is widely practiced, e.g., by British doctors attend-
ing a meeting in Egypt [35] and in profit-oriented
vaccination centers. At the current New York price
of $35.00 for two injections, with an incidence of
11500,000 travelers and a case fatality rate of 1.6070
[14],over a billion dollars would be spent to prevent
one fatal case of cholera. This vaccination should
be restricted to those visiting the fewremaining coun-
tries continuing to request a certificate despite the
1973 World Health Assembly recommendations [36].
Only 8.5070 of all travelers suffered from "severe"
diarrhea. This is far less than in our former survey
of travelers' diarrhea [15] because in this study we
concentrated on chronic or incapacitating forms.
One of the goals was to determine the rate of para-
sitic and bacterial intestinal infections in an un-
selected group consisting of mainly vacationers af-
ter their return home. The true infection rate is higher
because it is known for giardiasis [37], amebiasis [38]
(exceptionally in helminthiasis [39]), and salmonel-
losis that asymptomatic course and spontaneous
eradication may occur, but this proportion is of
Typhoid lever 110 11)
Shrqe llosrs (12)
Cholera 113 14)
.1
10
Travelers" diarrhea (151
Retrospective surveys
100,000 IWlth reference I
"12.998 '"
10,000
..... "19Shigellosis
This study
(only definite cases)
··Severe" diarrhea ..
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smaller practical consequence. Diarrhea occurring
after return home tended to last longer and to be-
come chronic compared with cases occurring while
abroad [15]. This may result from parasitoses that
have incubation periods ranging from weeks to
months [20].
Serious accidents rarely occurred - only 1% of the
travelers had to be hospitalized. Nevertheless,
travelers ought to be reminded to wear shoes while
swimming over coral reefs and to carefully disinfect
any laceration, however small it may be. These two
measures alone would avoid a substantial propor-
tion of the cases with subsequent inability to work.
The slightly higher incidence of trauma in the control
cohort may be associated with the lower average
age - young people being more prone to sports and
traffic accidents. No fatalities were recorded. Even
in Peace Corps volunteers, who may be more exposed
to danger than are vacationers, the rate was only
1/1,000 persons-years [40].
References
1. Kendrick MA. Study of illness among Americans returning
from international travel, July 11-August 24, 1971, pre-
liminary data. J Infect Dis 1972;126:684-5
2. Gangarosa EJ, Kendrick MA, Lowenstein MS, Merson MH,
Mosely JW. Global travel and travelers' health. Aviat Space
Environ Med 1980;51:265-70
3. Steffen R, Van der Linde F, Meyer HE. Erkrankungrisiken
bei 10500 Tropen- und 1300 Nordamerika-Touristen.
Schweiz Med Wochenschr 1978;108:1485-95
4. Lobel HO, Campbell CC, Schwartz IK, Roberts JM. Recent
trends in the importation of malaria caused by Plasmo-
dium falciparum into the United States from Africa. J In-
fect Dis 1985;152:613-7
5. Steffen R, Regli P, Grob PJ. Wie gross ist das Risiko einer
Reisehepatitis? Retrospektive Studie in der Region Ziirich
1971-1976. Schweiz Med Wochenschr 1977;107:1300-7
6. Skinhej P, Gluud C, Ramsoe K. Traveller's hepatitis. Origin
and characteristics of cases in Copenhagen 1976-1978.
Scand J Infect Dis 1981;13:1-4
7. Apotheloz M, Grob PJ, Steffen R, Schar M. Welchen Aus-
landreisenden ist en Impfschutz gegen Hepatitis zu emp-
fehelen? Soz Praventivmed 1982;27:264-5
8. Hall SM, Mortimer PP, Vandervelde EM. Hepatitis A in the
traveller. Lancet 1983;2:1198
9. Christenson B. Epidemiological aspects of acute viral hepa-
titis A in Swedish travelers to endemic areas. Scand J In-
fect Dis 1985;17:5-10
10. Steffen R. Typhoid vaccine, for whom? Lancet 1982;1:615-6
11. Taylor DN, Pollard RA, Blake PA. Typhoid in the United
States and the risk to the international traveler. J Infect
Dis 1983;148:599-602
12. Steffen R, Schar G, Mosimann J. Salmonella and Shigella
infections in Switzerland, with special reference to typhoid
vaccination for travellers. Scand J Infect Dis 1981;13:121-7
Steffen et al.
13. Snyder JD, Blake PA. Is cholera a problem for US travelers?
JAMA 1982;247:2268-9
14. Morger H, Steffen R, Schar M. Epidemiology of cholera in
travellers, and conclusions for vaccination recommenda-
tions. Br Med J 1983;286:184-6
15. Steffen R, Van der Linde F, Gyr K, Schar M. Epidemiology
of diarrhea in travelers. JAMA 1983;249:1176-80
16. Kozicki M, Steffen R, Schar M. "Boil it, cook it, peel it or
forget it". Does this rule prevent travellers' diarrhoea? Int
J Epidemiol 1985;14:169-72
17. Consensus conference. Travelers' diarrhea. JAMA 1983;253:
2700-4
18. Bundesamt fur Statistik. Reiseverkehr der Schweizer im Aus-
land 1984. Bern: Bundesamt fur Statistik 1985
19. Weise HJ. Die Entwicklung des internationalen Tourismus
und des nationalen Urlaubsverhaltens. Bundesgesundheits-
blatt 1982;25:275-9
20. Benenson AS. Control of communicable diseases in man. 14th
ed. Washington, DC: American Public Health Associa-
tion, 1985:7, 157, 160, 169, 383
21. Lobel HO, Campbell Cc. Malaria prophylaxis and distribu-
tion of drug resistance. Clin Trop Med Commun Dis
1986;1:225-41
22. Centers for Disease Control. Revised recommendations for
preventing malaria in travelers to areas with chloroquine-
resistant Plasmodiumfalciparum. MMWR 1985;34:185-95
23. Steffen R, Somaini B. Severe cutaneous adverse reactions to
sulfadoxine-pyrimethamine in Switzerland. Lancet
1986;1:610
24. Hatton CSR, Peto TEA, Bunch C, Pasvol G, RussellSJ, Singer
CRJ, Edwards G, Winstanley P. Frequency of severe neu-
tropenia associated with amodiaquine prophylaxis against
malaria. Lancet 1986;1:411-4
25. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J. Amodia-
quine induced agranulocytosis and liver damage. Br Med
J 1986;292:721-3
26. Lobel HO, Roberts J, Somaini B, Steffen R. Efficacy of
malaria prophylaxis in American and Swiss travelers to
Kenya. J Infect Dis 1987;156:1205-1209
27. WejstalR, Lindberg J, Malmvall B-E, Norkrans G. Liver dam-
age associated with Fansidar. Lancet 1986;1:854-5
28. Centers for Disease Control. Health information for inter-
national travel 1986.Atlanta: Centers for Disease Control,
1986:86, 110
29. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of
the term "cost effective" in medicine. N Engl J Med
1986;314:253-6
30. Immunization Practices Advisory Committee. (ACIP). Re-
commendations for protection against viral hepatitis.
MMWR 1985;34:313-24, 329- 35
31. Joshi YK, Babu S, Sarin S, Tandon BN, Gandhi BM,
Chaturvedi VC. Immunoprophylaxis of epidemic non-A
non-B hepatitis. Indian J Med Res 1985;81:18-9
32. Wuthrich RP, Somaini B, Steffen R, Hirschel B. Typhus-
epidemiologie in der Schweiz 1980-1983. Geringe oder feh-
lende Wirksamkeit des lebendimpfstoffes rivotifbei tropen-
reisenden. Schweiz Med Wochenschr 1985;115:1714-20
33. Leach RD. Medical aspects of ocean yacht voyages. navel
and Traffic Medicine International 1984;2:31-4
34. Allard R. Problems in adequately immunizing international
travellers. Can Med Assoc J 1983;128:40-1
Health Problems After Travel
35. Mitchell ABS. Foreign travel and health: mutually exclusive?
Practitioner 1985;229:827-30
36. World Health Organization. Vaccination certificate require-
ments and health advice for international travel. Geneva:
WHO. 1985
37. Jokipii L, Jokipii AM. Giardiasis in travelers: a prospective
study. J Infect Dis 1974;130:295-9
38. Nanda R, Baveja U, Anand BS. Entamoeba histolytica cyst
passers: clinical features and outcome in untreated sub-
jects. Lancet 1984;2:301-3
91
39. Croll NA, Anderson RM, Gyorkos TW, Ghadirian E. The
population biology and control of Ascaris lumbricoides
in a rural community in Iran. Tran R Soc Trop Med Hyg
1982;76:187-97
40. Hargarten SW. Baker SP. Fatalities in the Peace Corps. A
retrospective study: 1962 through 1983. JAMA 1985;
254:1326-9
